63-68-3 Usage
Feed additives
L-Methionine is mainly used as feed nutritional supplements and one of the essential amino acids in the growth of animals, which is the "skeleton" amino acid in protein biosynthesis and main donor of methyl in animal body. L-Methionineplays a certain role in the process of synthesis of choline by adrenal hormone and fatty liver phospholipids during the process of metabolism of the animal in vivo. Lacking of L-Methioninein livestock and poultry will lead to poor development, weight loss, liver and kidney function decline, muscle atrophy, fur deterioration, etc.
L-Methionine is a sulfur amino acid and the second limiting essential amino acids for pigs. The utilization ratio of feed protein can be improved effectively if lysine and L-Methioninewere added in the feed appropriately. So the lysine and L-Methionineare called enhancer for protein feed. Naturally occurring L-Methioninehas two types: D type and L type two and their biological utilization rate is identical. Synthetic L-Methionineis a type DL compound of type D and type L. The biological potency of compound is the same as that of the single D or L-methionine. The appearance of DL methionine additive is white to pale yellow crystal or crystalline powder and insoluble in water and has slightly sweetness haste. The content of L-Methioninein feed of pig is generally from 0.05% to 0.1%.
L-Methionineas a nutritional supplement, the effect of the type L is the same as that of the type of DL (due to the type L transformed from the type DL). Feed additives; as the product and cysteine both belong to sulfur-containing amino acids, so a large amount of them exist in animal proteins. However, it belongs to limiting amino acids in plant proteins such as oats, rye, rice, corn, wheat, peanuts, soybeans, potatoes, spinach and other vegetable foods and the content is less than animal proteins.So it can be added to the above food to improve the balance of amino acids. In the past, sulphur-containing amino acids were thought to be only suitable for non-ruminants. But now the experiment has been proved that it is applicable to the non-ruminants. It is more suitable for chicken and pig feed. On the medical side, it can be used for infusion together with other amino acids. Also used as a culture medium during fermentation.
Pharmacodynamics
L-Methionineis a sulfur-containing amino acid. Choline is synthesized in vivo by the L-Methioninesupplying the required methyl. And choline is a component of lecithin. Lecithin is an essential material for the removal of fat from the liver and the deposition of fat in the liver. So L-Methioninealso has an effect in choline lipotropic. In addition, L-Methioninein vivo supplies sulfur to synthesize non-exogenous amino acid Cys. The latter has the function of detoxification. Therefore, this medicine is used for the liver lipotropic in clinical , which is Suitable for fatty liver and chronic hepatitis and liver cirrhosis with fat infiltration. Clinical L-Methioninecan also be used as an adjuvant therapy drug for alcohol and poisoning.
Amino acids
Amino acids are the constituent units of the protein and are the material basis of life. From as large as human beings to as small as microorganism, they are both made up of proteins. Proteins are composed of peptides and peptide chains of peptides are composed of amino acids. Different proteins are made of peptide chains which are composed of amino acids in a different order and length. Genetically related genes are actually different sequences of amino acid chains. At present, there are total 28 kinds of amino acids related to the human body. These 28 amino acids are arranged in a different order and different length of the chain to compose the various parts proteins of the body. Of these 28 kinds of amino acids, nine species (about 32%) are required by the direct supply of dietary protein amino acids. They cannot be synthesized by other amino acids in the proteins that are taken in by the human body. They are leucine, isoleucine, valine, lysine, methionine, tryptophan, threonine, phenylalanine and histidine.
L-Methionineis an essential amino acid. It can help break down fat. So it can prevent fatty liver, heart disease, cerebrovascular disease and renal disease. The synthesis of amino acids, such as cysteine and taurine, requires the assistance of methionine.
This amino acid can help to remove harmful substances, such as lead and other heavy metals. It can prevent muscle weakness and brittle hair. It is also good for the prevention and treatment of osteoporosis or chemical allergies. It is good for the treatment of rheumatic fever and pregnancy toxemia.
L-Methionineis still a potent antioxidant. The sulfur L-Methioninewhich contains can eliminate free radicals. The synthesis of nucleic acids, collagen and protein in the body all require methionine. It is also good to take L-Methioninefor women taking contraceptives. Because the level of histamine in the blood of patients with schizophrenia is much higher than that of normal people, it can reduce the level of histamine in the body. Therefore, it is effective for the treatment of schizophrenia. If the body's toxic substances increase, the need for L-Methioninealso increases. As the body can change the L-Methionineinto cysteine, and cysteine is the precursor of glutathione; and glutathione is the main toxic liver neutralizers. So it will be able to protect the liver from harm toxic substances.
Methionine-rich foods: beans, other legumes, eggs, fish, garlic, meat, onions and yogurt.
Toxicity
LD50 36g/kg (rat, oral)
Safe for food (FDA§172.320,2000)
Originator
Meonine ,Ives,US,1944
Production Methods
Numerous methods have been described for manufacture of
methionine, including hydrolysis of methionine amide )and 5-(bmethylmercaptoethyl)-
hydantoin.
Manufacturing Process
A 3-necked flask fitted with a stirrer, thermometer, gas inlet, dropping funnel, and brine-cooled reflux condenser was charged with 53 g (1.1 mol) methyl mercaptan and 0.35 g mercuric methyl mercaptide. After admitting 56 g (1.0mol) of acrolein during the course of 15 minutes with an inside temperature of
about 10°C, the temperature was allowed to rise spontaneously to 75°C, at
which point an ice bath was applied. There was no indication of further
reaction one hour after the addition of the acrolein. Distillation of the product
gave 71 g (yield 68%) of β-methylmercaptopropionaldehyde, as described in
US Patent 2,584,496.Then as described in US Patent 2,732,400, β-methylmercaptopropionaldehyde
(0.60 M) (56.5 g) is added to a stirred solution of sodium cyanide (0.66 M)
(32.4 g) and ammonium chloride (0.63 M) (33.7 g) in water (140 ml). The
temperature of the mixture rises to 49°C and is maintained at this point by
heat evolution for about 5 minutes when it slowly begins to fall. Methanol (50
ml) is added and the mixture is stirred for 4 hours as the temperature falls to
28°C (room temperature).After chilling to +12°C, additional methanol (35 ml) and a concentrated
aqueous ammoniun hydroxide solution (1.4 M) (100 ml) are added and
stirring is continued for 2 hours at a temperature maintained at from +5° to
+15°C. The organic layer is separated and solvent is stripped from the
aqueous layer at water aspirator pressure at a temperature below 40°C. The
residue is extracted several times with chloroform and the chloroform extracts
are combined with the separated oil. Chloroform is removed at water aspirator
pressure at a temperature below 35°C to leave crude α-amino-γmethylmercaptobutyronitrile (methionine nitrile) in 88% yield (68 g) as a
clear, somewhat viscous oil.The methionine nitrile (20 g) is dissolved in a solution prepared from 50 ml of
aqueous 5 N sodium hydroxide solution and 65 ml of ethanol. The solution is
then refluxed for 24 hours; ammonia is evolved. The solution is treated with
activated carbon, filtered, acidified with glacial acetic acid (17 ml), chilled to -
10°C and filtered to give crude product. This crude product is then slurried
with a solution made up of 20 ml of water and 20 ml of methanol, filtered at -
5° to +10°C and dried to give dl-methionine as white platelets.
Therapeutic Function
Lipotropic
Synthesis Reference(s)
Canadian Journal of Chemistry, 47, p. 3271, 1969 DOI: 10.1139/v69-542Synthetic Communications, 26, p. 3619, 1996 DOI: 10.1080/00397919608003774
Air & Water Reactions
Reacts with water, steam, and/or acids to produce toxic and flammable vapors of hydrogen sulfide . Water soluble . pH of 1% aqueous solution is 5.6-6.0.
Reactivity Profile
An organosulfide and amine derivative, carboxylic acid. Look at Reactive Groups 20 (organosulfides), 7 (amines), and 3 (carboxylic acids) may give indications about reactive tendencies. L-Methionine is an amino acid essential in human nutrition.
Health Hazard
ACUTE/CHRONIC HAZARDS: L-Methionine is dangerous when heated to decomposition; it emits dangerous and highly toxic fumes.
Fire Hazard
Flash point data for L-Methionine is not available, but L-Methionine is probably combustible.
Pharmaceutical Applications
Methionine is used in oral pharmaceutical formulations as a
flavoring agent.It has been included in parenteral formulations as
a pH controlling agent,and it has also been used experimentally
as an antioxidant with antibodies.Methionine is also used
therapeutically in oral tablets
Biochem/physiol Actions
L-Methionine serves as precursor for transmethylation and transsulphuration. Methionine adenosylation results in the formation of S-adenosyl-L-methionine (SAM). SAM serves as a methyl donor to a number of substances. This methylation is significantly associated with the immune system functioning. Thus, SAM deficiency causes severe combined immunodeficiencies. L-Methionine′s metabolic product, glutathione, is known to regulate immune response and has antiviral action.
Safety Profile
Mildly toxic by
ingestion and intraperitoneal routes. Human
mutation data reported. An experimental
teratogen. Experimental reproductive
effects. An essential sulfur-containing amino
acid. When heated to decomposition it emits
very toxic fumes of NOx and SOx.
Safety
Methionine is used in oral pharmaceutical formulations. The pure
form of methionine is mildly toxic by ingestion and by the IP route.
LD50 (rat, IP): 4.328 g/k
LD50 (rat, oral): 36 g/kg
storage
Methionine is sensitive to light and should be stored in a cool, dark
place.
Purification Methods
Crystallise L-methionine from aqueous EtOH. Also purify it by dissolving ~0.5g of amino acid in ~10mL of hot H2O, filtering, adjusting the pH to 5.8 with 5N HCl, collecting the solid after addition of ~20mL of EtOH. It is recrystallised by dissolving in H2O and adding EtOH. It sublimes at 197-208o/0.3mm with 99.8% recovery and unracemised [Gross & Gradsky J Am Chem Soc 77 1678 1955]. [Milne & Peng J Am Chem Soc 79 647 1957, Greenstein & Winitz The Chemistry of the Amino Acids J. Wiley, Vol 3 pp 2125-2152 1961, Beilstein 4 IV 3189.]
Incompatibilities
Methionine is incompatible with strong oxidizing agents.
Regulatory Status
Included in the FDA Inactive Ingredients Database (oral tablets).
Included in parenteral preparations (injection solutions; powders
for reconstitution) licensed in the UK.
Check Digit Verification of cas no
The CAS Registry Mumber 63-68-3 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 63-68:
(4*6)+(3*3)+(2*6)+(1*8)=53
53 % 10 = 3
So 63-68-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
63-68-3Relevant articles and documents
Highly Stable Zr(IV)-Based Metal-Organic Frameworks for Chiral Separation in Reversed-Phase Liquid Chromatography
Jiang, Hong,Yang, Kuiwei,Zhao, Xiangxiang,Zhang, Wenqiang,Liu, Yan,Jiang, Jianwen,Cui, Yong
supporting information, p. 390 - 398 (2021/01/13)
Separation of racemic mixtures is of great importance and interest in chemistry and pharmacology. Porous materials including metal-organic frameworks (MOFs) have been widely explored as chiral stationary phases (CSPs) in chiral resolution. However, it remains a challenge to develop new CSPs for reversed-phase high-performance liquid chromatography (RP-HPLC), which is the most popular chromatographic mode and accounts for over 90% of all separations. Here we demonstrated for the first time that highly stable Zr-based MOFs can be efficient CSPs for RP-HPLC. By elaborately designing and synthesizing three tetracarboxylate ligands of enantiopure 1,1′-biphenyl-20-crown-6, we prepared three chiral porous Zr(IV)-MOFs with the framework formula [Zr6O4(OH)8(H2O)4(L)2]. They share the same flu topological structure but channels of different sizes and display excellent tolerance to water, acid, and base. Chiral crown ether moieties are periodically aligned within the framework channels, allowing for stereoselective recognition of guest molecules via supramolecular interactions. Under acidic aqueous eluent conditions, the Zr-MOF-packed HPLC columns provide high resolution, selectivity, and durability for the separation of a variety of model racemates, including unprotected and protected amino acids and N-containing drugs, which are comparable to or even superior to several commercial chiral columns for HPLC separation. DFT calculations suggest that the Zr-MOF provides a confined microenvironment for chiral crown ethers that dictates the separation selectivity.
Direct monitoring of biocatalytic deacetylation of amino acid substrates by1H NMR reveals fine details of substrate specificity
De Cesare, Silvia,McKenna, Catherine A.,Mulholland, Nicholas,Murray, Lorna,Bella, Juraj,Campopiano, Dominic J.
supporting information, p. 4904 - 4909 (2021/06/16)
Amino acids are key synthetic building blocks that can be prepared in an enantiopure form by biocatalytic methods. We show that thel-selective ornithine deacetylase ArgE catalyses hydrolysis of a wide-range ofN-acyl-amino acid substrates. This activity was revealed by1H NMR spectroscopy that monitored the appearance of the well resolved signal of the acetate product. Furthermore, the assay was used to probe the subtle structural selectivity of the biocatalyst using a substrate that could adopt different rotameric conformations.
Motobamide, an Antitrypanosomal Cyclic Peptide from a Leptolyngbya sp. Marine Cyanobacterium
Iwasaki, Arihiro,Jeelani, Ghulam,Kurisawa, Naoaki,Matsubara, Teruhiko,Nozaki, Tomoyoshi,Sato, Toshinori,Suenaga, Kiyotake,Suzuki, Ryota,Takahashi, Hiroki
, p. 1649 - 1655 (2021/05/29)
Motobamide (1), a new cyclic peptide containing a C-prenylated cyclotryptophan residue, was isolated from a marine Leptolyngbya sp. cyanobacterium. Its planar structure was established by spectroscopic and MS/MS analyses. The absolute configuration was elucidated based on a combination of chemical degradations, chiral-phase HPLC analyses, spectroscopic analyses, and computational chemistry. Motobamide (1) moderately inhibited the growth of bloodstream forms of Trypanosoma brucei rhodesiense (IC50 2.3 μM). However, it exhibited a weaker cytotoxicity against normal human cells (IC50 55 μM).
Process for producing L-methionine from methional
-
Page/Page column 5; 8; 9, (2021/02/17)
A method is useful for the biocatalytic synthesis of proteinogenic L-amino acids, such as L-alanine, L-valine, L-methionine, L-leucine, L-isoleucine or L-phenylalanine from a respective aldehyde and carbon dioxide. In particular, the method is useful for the biocatalytic synthesis of L-methionine from 3-methylthio-propanal (“methional”) and carbon dioxide.
Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
-
, (2020/04/10)
Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
Mutations of key substrate binding residues of leishmanial peptidase T alter its functional and structural dynamics
Bhat, Saleem Yousuf,Qureshi, Insaf Ahmed
, (2019/11/11)
Background: M20 aminopeptidases, such as Peptidase T (PepT), are implicated in the hydrolysis of oligopeptides during the terminal stages of protein degradation pathway to maintain turnover. Therefore, specific inhibition of PepT bores well for the development of novel next-generation antileishmanials. This work describes the metal dependence, substrate preferences and inhibition of PepT, and demonstrates in detail the role of its two conserved substrate binding residues. Methods: PepT was purified and characterized using a scheme of peptide substrates and peptidomimetic inhibitors. Residues T364 and N378 were mutated and characterized with an array of biochemical, biophysical and structural biology methods. Results: PepT sequence carries conserved motifs typical of M20 peptidases and our work on its biochemistry shows that this cytosolic enzyme carries broad substrate specificity with best cleavage preference for peptides carrying alanine at the P1 position. Peptidomimetics amastatin and actinonin occupied S1 pocket by competing with the substrate for binding to active site and inhibited PepT potently, while arphamenine A and bestatin were less effective inhibitors. We further show that the mutation of conserved substrate binding residues (T364 and N378) to alanine affects structure, reduces substrate binding and alters the amidolytic activity of this dimeric enzyme. Conclusions: PepT preferentially hydrolyzes oligopeptides carrying alanine at P1 position and is potently inhibited by peptidomimetics. Reduced substrate binding after mutations was a key factor involved in amidolytic digressions. General significance: This study provides insights for further exploration of the druggability of PepT and highlights prospective applications of this enzyme along with its mutazyme T364A/N378A.
Ultrasound-Controlled Chiral Separation of Four Amino Acids and 2,2,2-Trifluoro-1-(9-anthryl)ethanol
Lee, Jae Hwan,Ryoo, Jae Jeong
, p. 146 - 149 (2019/02/07)
Chiral separation of 4-hydroxyphenylglycine, phenylglycine, tryptophan, methionine, and 2,2,2-trifluoro-1-(9-anthryl)ethanol (TFAE) was performed under ultrasound reduction at room temperature and high temperature (50 °C). At high temperature (50 °C), both α and Rs were improved slightly under ultrasound reduction as compared to those under non-ultrasonic and ultrasonic irradiation (50 watt/L) conditions. Even at low temperatures, the largest α was observed under ultrasound reduction conditions, except in the case of methionine. However, at low temperature, Rs was reduced under ultrasound (50 watt/L) irradiation, but was improved under ultrasound reduction rather than under the continuous ultrasonic irradiation. Similar to the fact that gradient elution (based on solvent polarity) can improve α, ultrasound reduction can improve α and Rs. Ultrasound reduction is demonstrated to aid the rapid separation of chiral compounds with improved resolution, especially, at high temperatures. Although chromatographic separation using ultrasound has been rarely dealt with until now, ultrasound can be used as an external field in chromatography.
Light-Driven Kinetic Resolution of α-Functionalized Carboxylic Acids Enabled by an Engineered Fatty Acid Photodecarboxylase
Xu, Jian,Hu, Yujing,Fan, Jiajie,Arkin, Mamatjan,Li, Danyang,Peng, Yongzhen,Xu, Weihua,Lin, Xianfu,Wu, Qi
supporting information, p. 8474 - 8478 (2019/05/24)
Chiral α-functionalized carboxylic acids are valuable precursors for a variety of medicines and natural products. Herein, we described an engineered fatty acid photodecarboxylase (CvFAP)-catalyzed kinetic resolution of α-amino acids and α-hydroxy acids, which provides the unreacted R-configured substrates with high yields and excellent stereoselectivity (ee up to 99 %). This efficient light-driven process requires neither NADPH recycling nor prior preparation of esters, which were required in previous biocatalytic approaches. The structure-guided engineering strategy is based on the scanning of large amino acids at hotspots to narrow the substrate binding tunnel. To the best of our knowledge, this is the first example of asymmetric catalysis by an engineered CvFAP.
Structural and functional highlights of methionine aminopeptidase 2 from Leishmania donovani
Bhat, Saleem Yousuf,Dey, Arijit,Qureshi, Insaf A.
, p. 940 - 954 (2018/05/23)
Methionine aminopeptidase 2 (MAP2) is a principal regulator of apoptosis for Leishmania donovani and a potential candidate for the design and synthesis of novel antileishmanials. The LdMAP2 gene was cloned in pET28a(+)-SUMO vector, expressed in E. coli and then purified by chromatographic methods. It was found to be a monomer and required divalent metal ion for its activity against synthetic substrates with Co(II), Mg(II), Mn(II) and Ni(II) being the major activators. Moreover, Ca(II) showed the tightest binding with Km value of 124.7 ± 9.2 μM, while Co(II) proved most efficient for catalysis with kcat value of 128.1 ± 4 min?1. The naturally occurring aminopeptidase B inhibitor bestatin was found to be a potent inhibitor of LdMAP2 with a Ki value of 0.86 μM. Further, structural studies with circular dichroism (CD) showed an increase in the α-helical and β-sheet contents and a decrease in random coils in LdMAP2 upon interactions with both bestatin and fluorogenic substrates. Finally, structural studies pointed out key differences in the structure of LdMAP2 and HsMAP2 and their interactions with inhibitor bestatin, Ala-AMC, Leu-AMC and Met-AMC. The structural differences of two orthologs and different binding modes with bestatin can be crucial for the development of novel and specific inhibitor against leishmaniasis.
The identification of inhibitory compounds of Rickettsia prowazekii methionine aminopeptidase for antibacterial applications
Helgren, Travis R.,Seven, Elif S.,Chen, Congling,Edwards, Thomas E.,Staker, Bart L.,Abendroth, Jan,Myler, Peter J.,Horn, James R.,Hagen, Timothy J.
, p. 1376 - 1380 (2018/04/11)
Methionine aminopeptidase (MetAP) is a dinuclear metalloprotease responsible for the cleavage of methionine initiator residues from nascent proteins. MetAP activity is necessary for bacterial proliferation and is therefore a projected novel antibacterial
